SCYNEXIS Announces Positive Results from Interim Analyses of Ong
134
SCYX: Scynexis 2021-03-02 07:30:00 SCYNEXIS Announces Positive Results from Interim Analyses of Ongoing Phase 3 Studies (FURI and CARES), Demonstrating Oral Ibrexafungerp's Ability to Treat Severe Fungal Infections in the Hospital Setting